[Skip to Content]

Statements

New outpatient tariffs and the impact on ophthalmology – managing change for commissioning services

Feb 22
2017

The RCOphth has issued a further response to the December 2016 statement on how the new outpatient tariffs place unnecessary pressure on departments to discharge patients at a time when there is no suitable community care option available. You can read the response below or alternatively download it as a pdf. What are the potential patient safety risks in

  • 22 February 2017

Statement on proposed new 2017/18 and 2018/19 National Tariff Payment System

Dec 09
2016

The Royal College of Ophthalmologists (RCOphth) notes that this consultation was primarily for commissioners and providers under Section 118 of the Health & Social Care Act.  However, we have responded to the consultation as we feel strongly that the 2017/18 and 2018/19 National Tariff Payment System1 disadvantages some of the more vulnerable groups of eye

  • 9 December 2016

GMC concerned about ‘state of unease’ in medical profession

Oct 27
2016

The General Medical Council (GMC) has raised concerns that a ‘state of unease’ exists within the medical profession as services throughout the UK come under increased pressure. The medical regulator’s warning that systems of healthcare and the health professionals working within them are struggling to cope with a range of issues – including the impact

  • 27 October 2016

RCOphth strongly recommends orthoptist led UK National Screening programme for children

Sep 15
2016

The Royal College of Ophthalmologists strongly recommends that the orthoptist led UK National Screening programme for children is implemented across all local authorities The UK National Screening Committee (NSC) has recommended orthoptist led screening for visual impairment in all children aged 4 – 5 years. http://www.screening.nhs.uk/vision-child From October 2015, responsibility for the funding of vision screening

  • 15 September 2016

NICE Macular Oedema (Branch Retinal Vein Occlusion) Final Technology Appraisal

Aug 26
2016

Response to NICE announcing their positive final guidance for Eylea® for the treatment of adult patients with visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO) The Royal College of Ophthalmologists welcomes the Final Appraisal Determination (FAD) from NICE recommending Eylea (aflibercept) as a first-line treatment option for patients with visual

  • 26 August 2016